West Pharmaceutical Services Company Profile (NYSE:WST)

About West Pharmaceutical Services (NYSE:WST)

West Pharmaceutical Services logoWest Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company's products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. The Company's segments include Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment develops commercial and operational strategies across its global network, with specific emphasis on product offerings to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as an integrated business focused on the design, manufacture and automated assembly of various devices, primarily for pharmaceutical, diagnostic and medical device customers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Health Care Supplies
  • Symbol: NYSE:WST
  • CUSIP: 95530610
  • Web: www.westpharma.com
  • Market Cap: $6.85 billion
  • Outstanding Shares: 74,002,000
Average Prices:
  • 50 Day Moving Avg: $93.61
  • 200 Day Moving Avg: $91.64
  • 52 Week Range: $70.17 - $99.91
  • Trailing P/E Ratio: 40.27
  • Foreward P/E Ratio: 31.79
  • P/E Growth: 1.92
Sales & Book Value:
  • Annual Revenue: $1.54 billion
  • Price / Sales: 4.45
  • Book Value: $16.79 per share
  • Price / Book: 5.51
  • Annual Dividend: $0.56
  • Dividend Yield: 0.6%
  • EBITDA: $317.9 million
  • Net Margins: 11.42%
  • Return on Equity: 14.02%
  • Return on Assets: 9.32%
  • Debt-to-Equity Ratio: 0.16%
  • Current Ratio: 2.48%
  • Quick Ratio: 1.75%
  • Average Volume: 433,743 shs.
  • Beta: 1.12
  • Short Ratio: 4.24

Frequently Asked Questions for West Pharmaceutical Services (NYSE:WST)

What is West Pharmaceutical Services' stock symbol?

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

How often does West Pharmaceutical Services pay dividends? What is the dividend yield for West Pharmaceutical Services?

West Pharmaceutical Services declared a quarterly dividend on Thursday, July 20th. Stockholders of record on Wednesday, October 18th will be given a dividend of $0.14 per share on Wednesday, November 1st. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend is Tuesday, October 17th. This is a boost from West Pharmaceutical Services's previous quarterly dividend of $0.13. View West Pharmaceutical Services' Dividend History.

How were West Pharmaceutical Services' earnings last quarter?

West Pharmaceutical Services, Inc. (NYSE:WST) announced its quarterly earnings results on Thursday, July, 27th. The company reported $0.66 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.65 by $0.01. The company had revenue of $397.60 million for the quarter, compared to analyst estimates of $406 million. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. During the same period last year, the company posted $0.59 EPS. View West Pharmaceutical Services' Earnings History.

When will West Pharmaceutical Services make its next earnings announcement?

West Pharmaceutical Services is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for West Pharmaceutical Services.

What guidance has West Pharmaceutical Services issued on next quarter's earnings?

West Pharmaceutical Services updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $2.66-2.73 for the period, compared to the Thomson Reuters consensus estimate of $2.67. The company issued revenue guidance of $1.585-1.6 billion, compared to the consensus revenue estimate of $1.61 billion.

Where is West Pharmaceutical Services' stock going? Where will West Pharmaceutical Services' stock price be in 2017?

5 brokerages have issued twelve-month price objectives for West Pharmaceutical Services' shares. Their predictions range from $98.00 to $115.00. On average, they anticipate West Pharmaceutical Services' share price to reach $104.00 in the next year. View Analyst Ratings for West Pharmaceutical Services.

What are analysts saying about West Pharmaceutical Services stock?

Here are some recent quotes from research analysts about West Pharmaceutical Services stock:

  • 1. According to Zacks Investment Research, "West Pharmaceutical Services applies technologies to the process of bringing new drug therapies and healthcare products. West's technologies include the design and manufacture of packaging components for pharmaceutical, healthcare and consumer products; research and development of drug delivery systems; contract manufacturing and packaging services; clinical services; and contract laboratory services and other services that support the manufacturing, filling and packaging of pharmaceutical, healthcare and consumer products. " (9/27/2017)
  • 2. Jefferies Group LLC analysts commented, "WST's formal '17 guidance featured a 1% higher CC revenue growth (7-9% from 6-8%) and continued margin expansion driven by high-value product growth. But that wasn't enough. At 33x '17, we thought the market discounted inflecting EPS growth, which has made valuation look stretched to us. FX headwinds ($35-45M; $0.05-0.07) and slightly rising tax rate negate the faster top-line. Maintain Hold." (2/21/2017)

Are investors shorting West Pharmaceutical Services?

West Pharmaceutical Services saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 1,670,580 shares, an increase of 50.0% from the August 31st total of 1,113,671 shares. Based on an average daily trading volume, of 536,299 shares, the days-to-cover ratio is currently 3.1 days. Approximately 2.3% of the company's stock are short sold.

Who are some of West Pharmaceutical Services' key competitors?

Who are West Pharmaceutical Services' key executives?

West Pharmaceutical Services' management team includes the folowing people:

  • Eric Mark Green, President, Chief Executive Officer, Director
  • William J. Federici, Chief Financial Officer, Senior Vice President, Treasurer
  • Annette F. Favorite, Chief Human Resource Officer, Senior Vice President
  • George Lloyd Miller J.D., Senior Vice President, General Counsel, Corporate Secretary
  • Karen A. Flynn, Senior Vice President and Chief Commercial Officer
  • David A. Montecalvo, Senior Vice President - Global Operations and Supply Chain
  • Eric Resnick, Chief Technology Officer, Vice President
  • Daniel Malone, Vice President, Corporate Controller
  • Michael A. Anderson, Vice President, Treasurer
  • Patrick J. Zenner, Non-Executive Independent Chairman of the Board

Who owns West Pharmaceutical Services stock?

West Pharmaceutical Services' stock is owned by a number of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (1.44%), Hermes Investment Management Ltd. (1.23%), Nationwide Fund Advisors (0.19%), Kistler Tiffany Companies LLC (0.09%), State Treasurer State of Michigan (0.04%) and Sit Investment Associates Inc. (0.01%). Company insiders that own West Pharmaceutical Services stock include Daniel Malone, Heino Lennartz, John E Paproski, Karen Flynn, Michael A Anderson, Patrick J Zenner, Paula A Johnson, Thomas W Hofmann, Warwick Bedwell and William J Federici. View Institutional Ownership Trends for West Pharmaceutical Services.

Who sold West Pharmaceutical Services stock? Who is selling West Pharmaceutical Services stock?

West Pharmaceutical Services' stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Nationwide Fund Advisors, Kistler Tiffany Companies LLC, Fox Run Management L.L.C. and State Treasurer State of Michigan. Company insiders that have sold West Pharmaceutical Services stock in the last year include Daniel Malone, Paula A Johnson and William J Federici. View Insider Buying and Selling for West Pharmaceutical Services.

Who bought West Pharmaceutical Services stock? Who is buying West Pharmaceutical Services stock?

West Pharmaceutical Services' stock was acquired by a variety of institutional investors in the last quarter, including Hermes Investment Management Ltd., Sit Investment Associates Inc. and Eqis Capital Management Inc.. View Insider Buying and Selling for West Pharmaceutical Services.

How do I buy West Pharmaceutical Services stock?

Shares of West Pharmaceutical Services can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is West Pharmaceutical Services' stock price today?

One share of West Pharmaceutical Services stock can currently be purchased for approximately $92.51.

MarketBeat Community Rating for West Pharmaceutical Services (NYSE WST)
Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  83 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  264
MarketBeat's community ratings are surveys of what our community members think about West Pharmaceutical Services and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for West Pharmaceutical Services (NYSE:WST) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $104.00 (12.42% upside)
Consensus Price Target History for West Pharmaceutical Services (NYSE:WST)
Price Target History for West Pharmaceutical Services (NYSE:WST)
Analysts' Ratings History for West Pharmaceutical Services (NYSE:WST)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/17/2017Bank of America CorporationDowngradeBuy -> Neutral$98.00N/AView Rating Details
10/3/2017StephensInitiated CoverageEqual -> Equal Weight$99.00MediumView Rating Details
9/15/2017Jefferies Group LLCUpgradeHold -> Buy$96.00 -> $115.00HighView Rating Details
12/23/2016Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
10/28/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 10/24/2015 forward)


Earnings History for West Pharmaceutical Services (NYSE:WST)
Earnings by Quarter for West Pharmaceutical Services (NYSE:WST)
Earnings History by Quarter for West Pharmaceutical Services (NYSE WST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$0.61N/AView Earnings Details
7/27/2017Q2 2017$0.65$0.66$406.00 million$397.60 millionViewN/AView Earnings Details
4/27/2017Q1 2017$0.55$0.81$380.42 million$387.70 millionViewN/AView Earnings Details
2/16/2017Q416$0.56$0.54$387.31 million$382.30 millionViewListenView Earnings Details
10/27/2016Q316$0.53$0.53$371.76 million$376.70 millionViewListenView Earnings Details
7/28/2016Q216$0.56$0.59$384.58 million$388.00 millionViewListenView Earnings Details
4/28/2016Q116$0.51$0.53$355.86 million$362.10 millionViewListenView Earnings Details
2/18/2016Q415$0.47$0.47$364.76 million$359.70 millionViewListenView Earnings Details
10/29/2015Q315$0.43$0.44$355.90 million$344.50 millionViewListenView Earnings Details
7/30/2015Q215$0.45$0.47$356.33 million$359.70 millionViewListenView Earnings Details
4/30/2015Q115$0.40$0.45$346.64 million$335.90 millionViewListenView Earnings Details
2/19/2015Q414$0.46$0.45$348.33 million$349.80 millionViewListenView Earnings Details
10/30/2014Q314$0.43$0.44$356.08 million$355.90 millionViewListenView Earnings Details
7/31/2014Q214$0.47$0.52$368.60 million$368.90 millionViewN/AView Earnings Details
5/1/2014Q114$0.41$0.38$340.90 million$346.80 millionViewListenView Earnings Details
2/20/2014Q413$0.38$0.38$348.70 million$342.70 millionViewListenView Earnings Details
10/31/2013Q3 13$0.36$0.39$333.25 million$341.80 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.82$0.86$349.85 million$344.50 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.86$0.87$344.20 million$339.40 millionViewListenView Earnings Details
2/21/2013Q4 2012$0.56$0.61$318.75 million$321.50 millionViewListenView Earnings Details
11/1/2012Q312$0.50$0.52$306.91 million$303.80 millionViewN/AView Earnings Details
8/2/2012$0.69$0.79ViewN/AView Earnings Details
4/26/2012$0.65$0.83ViewN/AView Earnings Details
2/16/2012$0.55$0.59ViewN/AView Earnings Details
11/1/2011$0.54$0.53ViewN/AView Earnings Details
7/28/2011$0.68$0.62ViewN/AView Earnings Details
4/28/2011$0.62$0.60ViewN/AView Earnings Details
2/17/2011$0.46$0.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for West Pharmaceutical Services (NYSE:WST)
2017 EPS Consensus Estimate: $2.34
2018 EPS Consensus Estimate: $2.98
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.55$0.55$0.55
Q2 20171$0.59$0.59$0.59
Q3 20171$0.54$0.54$0.54
Q4 20171$0.66$0.66$0.66
Q1 20181$0.83$0.83$0.83
Q2 20181$0.81$0.81$0.81
Q3 20181$0.63$0.63$0.63
Q4 20181$0.71$0.71$0.71
(Data provided by Zacks Investment Research)


Current Dividend Information for West Pharmaceutical Services (NYSE:WST)
Next Dividend:11/1/2017
Annual Dividend:$0.56
Dividend Yield:0.61%
Dividend Growth:8.40% (3 Year Average)
Payout Ratio:23.93% (Trailing 12 Months of Earnings)
20.97% (Based on This Year's Estimates)
19.24% (Based on Next Year's Estimates)
Track Record:24 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for West Pharmaceutical Services (NYSE:WST)

Dividend History by Quarter for West Pharmaceutical Services (NYSE WST)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for West Pharmaceutical Services (NYSE:WST)
Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 90.70%
Insider Trades by Quarter for West Pharmaceutical Services (NYSE:WST)
Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)
Insider Trades by Quarter for West Pharmaceutical Services (NYSE:WST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017William J. FedericiCFOSell54,996$95.45$5,249,368.20View SEC Filing  
5/2/2017Daniel MaloneVPSell4,124$93.31$384,810.44View SEC Filing  
12/8/2016Patrick J. ZennerDirectorBuy332$84.53$28,063.96View SEC Filing  
10/31/2016Paula A. JohnsonDirectorSell2,466$75.87$187,095.42View SEC Filing  
9/6/2016Karen FlynnSVPSell14,581$83.28$1,214,305.68View SEC Filing  
8/23/2016Paula A JohnsonDirectorSell3,042$81.55$248,075.10View SEC Filing  
6/2/2016Daniel MaloneVPSell3,950$74.95$296,052.50View SEC Filing  
5/25/2016Thomas W HofmannDirectorSell2,466$73.57$181,423.62View SEC Filing  
3/1/2016Michael A AndersonVPSell16,414$63.58$1,043,602.12View SEC Filing  
2/29/2016Thomas W HofmannDirectorSell3,042$62.70$190,733.40View SEC Filing  
2/25/2016Heino LennartzInsiderSell5,680$62.47$354,829.60View SEC Filing  
2/24/2016Heino LennartzInsiderSell19,658$59.45$1,168,668.10View SEC Filing  
2/23/2016Paula A. JohnsonDirectorSell7,800$59.39$463,242.00View SEC Filing  
2/22/2016Warwick BedwellInsiderSell16,042$59.52$954,819.84View SEC Filing  
11/25/2015John E. PaproskiinsiderSell17,560$63.41$1,113,479.60View SEC Filing  
11/12/2015Heino LennartzInsiderSell3,500$61.87$216,545.00View SEC Filing  
11/6/2015Michael A AndersonVPSell3,000$62.18$186,540.00View SEC Filing  
11/5/2015Michael A. AndersonVPSell10,000$61.98$619,800.00View SEC Filing  
11/4/2015Daniel MaloneVPSell4,456$61.65$274,712.40View SEC Filing  
8/17/2015William J FedericiCFOSell52,678$59.72$3,145,930.16View SEC Filing  
5/28/2015Heino LennartzInsiderSell9,584$55.00$527,120.00View SEC Filing  
5/22/2015Karen FlynnInsiderSell3,091$55.24$170,746.84View SEC Filing  
5/21/2015Eric Mark GreenCEOBuy18,300$54.89$1,004,487.00View SEC Filing  
5/18/2015Karen FlynnInsiderSell1,909$55.00$104,995.00View SEC Filing  
5/15/2015Donald E Morel JrCEOSell20,000$54.29$1,085,800.00View SEC Filing  
2/27/2015Richard D LuzziVPSell10,000$54.85$548,500.00View SEC Filing  
2/26/2015Michael A AndersonVPSell4,682$54.93$257,182.26View SEC Filing  
2/25/2015Heino LennartzInsiderSell3,617$54.82$198,283.94View SEC Filing  
2/24/2015John E PaproskiInsiderSell9,282$52.87$490,739.34View SEC Filing  
2/23/2015Heino LennartzInsiderSell21,040$53.40$1,123,536.00View SEC Filing  
2/23/2015Patrick J ZennerDirectorSell12,800$53.69$687,232.00View SEC Filing  
11/26/2014Richard D LuzziVPSell8,000$52.11$416,880.00View SEC Filing  
11/21/2014William J FedericiCFOSell3,000$51.22$153,660.00View SEC Filing  
11/20/2014Donald E Morel JrCEOSell20,000$51.30$1,026,000.00View SEC Filing  
11/13/2014John R GaileyVPSell28,000$52.37$1,466,360.00View SEC Filing  
11/11/2014Michael A AndersonVPSell4,600$51.73$237,958.00View SEC Filing  
11/10/2014Warwick BedwellInsiderSell6,306$49.95$314,984.70View SEC Filing  
8/21/2014Richard D LuzziVPSell10,000$44.07$440,700.00View SEC Filing  
8/20/2014John R GaileyVPSell20,000$43.96$879,200.00View SEC Filing  
8/19/2014Michael A AndersonVPSell9,800$43.41$425,418.00View SEC Filing  
8/18/2014William J FedericiCFOSell38,366$42.56$1,632,856.96View SEC Filing  
8/13/2014Heino LennartzInsiderSell7,555$39.65$299,555.75View SEC Filing  
8/11/2014Heino LennartzInsiderSell11,445$40.00$457,800.00View SEC Filing  
8/7/2014John E PaproskiInsiderSell14,000$40.44$566,160.00View SEC Filing  
5/30/2014Richard D LuzziVPSell22,828$42.17$962,656.76View SEC Filing  
5/29/2014Heino LennartzInsiderSell2,000$43.00$86,000.00View SEC Filing  
2/28/2014Heino LennartzInsiderSell16,044$45.84$735,456.96View SEC Filing  
2/26/2014Patrick J ZennerDirectorSell12,800$46.12$590,336.00View SEC Filing  
2/24/2014Warwick BedwellInsiderSell24,606$47.49$1,168,538.94View SEC Filing  
11/26/2013Donald E Morel JrCEOSell35,000$48.60$1,701,000.00View SEC Filing  
11/22/2013William J FedericiCFOSell36,000$48.34$1,740,240.00View SEC Filing  
11/19/2013Karen FlynnInsiderSell5,500$47.75$262,625.00View SEC Filing  
11/8/2013Michael A AndersonVPSell9,200$46.80$430,560.00View SEC Filing  
11/7/2013Heino LennartzInsiderSell5,102$46.70$238,263.40View SEC Filing  
11/6/2013Michael A AndersonVPSell6,000$46.53$279,180.00View SEC Filing  
11/5/2013John R GaileyVPSell6,000$46.83$280,980.00View SEC Filing  
11/5/2013Warwick BedwellInsiderSell6,304$46.84$295,279.36View SEC Filing  
11/4/2013Richard D LuzziVPSell38,708$46.99$1,818,888.92View SEC Filing  
8/30/2013Donald E Morel JrCEOSell10,000$74.46$744,600.00View SEC Filing  
8/27/2013John R GaileyVPSell13,749$76.77$1,055,510.73View SEC Filing  
8/22/2013L Robert JohnsonDirectorSell1,883$76.81$144,633.23View SEC Filing  
8/14/2013John E PaproskiInsiderSell6,011$79.08$475,349.88View SEC Filing  
8/12/2013Anthony WeltersDirectorSell19,200$78.43$1,505,856.00View SEC Filing  
8/8/2013Michael A AndersonVPSell4,300$78.00$335,400.00View SEC Filing  
5/31/2013Michael A AndersonVPSell4,000$68.94$275,760.00View SEC Filing  
5/28/2013Donald E Morel JrCEOSell10,000$67.87$678,700.00View SEC Filing  
5/24/2013L Robert JohnsonDirectorSell1,700$67.47$114,699.00View SEC Filing  
5/20/2013John R GaileyVPSell9,282$68.54$636,188.28View SEC Filing  
5/17/2013L Robert JohnsonDirectorSell4,000$67.80$271,200.00View SEC Filing  
5/8/2013L Robert JohnsonDirectorSell6,400$64.49$412,736.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for West Pharmaceutical Services (NYSE:WST)
Latest Headlines for West Pharmaceutical Services (NYSE:WST)
Loading headlines, please wait.



West Pharmaceutical Services (WST) Chart for Tuesday, October, 24, 2017

This page was last updated on 10/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.